drugset / Trial / NCT01600222

Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris

NCT01600222

Phase 2 Completed 37 enrolled LEO Pharma
NaSingle-groupOpen-labelTreatment

Summary

A Phase 2 Maximal Use Systemic Exposure (MUSE) study evaluating the safety and efficacy of LEO 90100 used once daily in subjects with extensive psoriasis vulgaris.

Timeline

Start
2012-05
Primary completion
2013-05
Completion
2013-05

Publications

  • Results Taraska V, Tuppal R, Olesen M, Bang Pedersen C, Papp K. Fixed combination aerosol foam calcipotriene (Cal) 0.005% plus betamethasone 0.064% (as dipropionate; BD) exhibits no impact on the HPA axis and calcium homeostasis in patients with extensive psoriasis vulgaris: a multicenter, single-arm, Phase II, 4-week MUSE study. Semin Cutan Med Surg. 2015;34 S1:PA-29.
  • Results Taraska V, Tuppal R, Olesen M, Bang Pedersen C, Papp K. Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) exhibits no impact on the HPA axis and calcium homeostasis in patients with extensive psoriasis vulgaris: a multicenter, single-arm, Phase II, 4-week MUSE study. Semin Cutan Med Surg 2014;33:abst PA-13.

Drugs

EvaluationDrugModalityDoseRoute
Subject Betamethasone Other / unclassified
Subject Calcipotriol Small molecule

Indications